A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Study Details
Study Description
Brief Summary
Individuals with stroke commonly experience both depression and cognitive difficulties. The goal of this study is to evaluate the efficacy of a treatment that combines a digital therapeutic (an iPad-based cognitive training program) with learning cognitive strategies. The hypotheses are that this treatment will improve cognitive skills, depression symptoms, daily function, and brain connectivity. In the short-term, the findings will inform the efficacy of the intervention and in the long-term, may support the use of the intervention to improve co-occurring cognitive and mood difficulties after stroke.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Post-stroke depression with executive dysfunction (DED) is associated with persistent mood and cognitive disturbance, poor social functioning, and disability. Existing interventions have limited evidence of efficacy, side effects, and can be difficult for stroke patients to access. This study aims to evaluate a remote digital intervention for post-stroke DED that combines iPad-based cognitive training using a program called AKL-T01 with virtual coaching to improve executive dysfunction, depression, and daily function after stroke. The primary hypothesis is that individuals randomized to the intervention arm (AKL-T01 + coaching) will demonstrate greater improvement in their executive functioning and depression symptoms and daily function relative to the comparator arm. The secondary hypothesis is that individuals randomized to the intervention arm will demonstrate greater increase in the functional connectivity of the executive control network (ECN, assessed with an MRI scan) at the conclusion of treatment, relative to participants randomized to the comparator arm.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: AKL-T01 Participants in the intervention group will complete 25 minutes of AKL-T01 per day, 5 days/week, for 6 weeks. AKL-T01 trains rapid multitasking on an iPad in an immersive videogame-like environment. Participants complete go/no-go + navigation exercises by moving the iPad to navigate a character on a path while tapping when a certain stimulus is presented and ignoring other stimuli. Participants will also receive weekly 45-minute metacognitive strategy coaching sessions delivered by a clinician. Sessions use guided questions and worksheets (shared virtually) to help participants reflect on their experience with AKL-T01 and link it to daily functioning, generate strategies for daily activities, and explore any emotional responses that arise during gameplay. |
Device: AKL-T01
AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
Behavioral: Metacognitive Strategy Training
Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
|
| Placebo Comparator: Enhanced Metacognitive Strategy Training In the control group, participants will complete-at the same frequency and duration as the intervention group-iPad-based games designed to provide general cognitive stimulation (word searches, checkers, and "spot the differences" between two pictures). Concurrently with these cognitive stimulation games, participants will receive weekly metacognitive strategy coaching sessions akin to that described above. |
Behavioral: Metacognitive Strategy Training
Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
|
Outcome Measures
Primary Outcome Measures
- Change in executive function, as measured by the Oral Symbol Digit Modalities Test (SDMT) [Baseline and end of treatment (6 weeks)]
Change in score in the active intervention arm vs. the comparator arm on the SDMT, a performance-based measure of divided attention/working memory with scores ranging from 0-120, with higher scores indicating better performance.
Secondary Outcome Measures
- Change in depression symptoms, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) [Baseline and end of treatment (6 weeks)]
Change in score in the active intervention arm vs. the comparator arm on the MADRS, a clinician-rated assessment of depression symptom severity that consists of 10 items; each item is rated on a 0-6 scale, resulting in a maximum total score of 60 points, with higher scores indicative of greater depression symptom severity.
- Change in depression symptoms, as measured by the 9-item Patient Health Questionnaire (PHQ-9) [Baseline and end of treatment (6 weeks)]
Change in score in the active intervention arm vs. the comparator arm on the PHQ-9, a self-report questionnaire of depression symptom frequency. Scores range from 0-27, where higher scores are indicative of greater depression symptoms.
- Change in daily function, as measured by the World Health Organization Disability Assessment Schedule (WHODAS 2.0) [Baseline and end of treatment (6 weeks)]
Change in score in the active intervention arm vs. the comparator arm on the WHODAS 2.0, a self-report measure of difficulty in everyday activities. Scores range from 36-180, with a higher number indicating more disability.
- Change in connectivity in the executive control network, as assessed by resting state functional MRI (rs-fMRI). [Baseline and end of treatment (6 weeks)]
Change in functional connectivity in the active intervention arm vs. the comparator arm assessed by an rs-fMRI scan.
- Change in executive function, as measured by the NIH Toolbox Flanker test [Baseline and end of treatment (6 weeks)]
Change in total score in the active intervention arm vs. the comparator arm on the NIH Toolbox Flanker test, a timed iPad-based test of executive function where participants have to respond to certain stimuli while ignoring distractors. Scoring is based on a combination of accuracy and reaction time.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
first-time stroke that occurred 6 months or more prior to study initiation
-
executive dysfunction as defined by a score of less than 1 standard deviation below age-adjusted normative score on at least one test of executive function in the screening assessment
-
diagnosis of Major Depressive Episode assessed by the Structured Clinical Interview for the DSM-5 (SCID).
-
at least moderate depressive symptoms as defined by Montgomery Asberg Depression Rating Scale ≥ 18
-
motor function sufficient to operate an iPad and use a pen, based on self-report and observation
-
if treated with an antidepressant medication, must be on a stable dose for a minimum of 8 weeks at the time of study enrollment.
Exclusion Criteria:
-
receptive aphasia as determined by a score <75% on the Western Aphasia Battery-Revised Auditory Comprehension
-
patient already enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is already enrolled in psychotherapy, this will not be grounds for exclusion)
-
non-fluency in English
-
presence of or history of significant neurologic or neurodegenerative disorder other than stroke
-
presence of dementia based on dependence in basic ADLs due to cognitive deficits
-
history of psychosis or mania (evaluated using the SCID).
-
active suicide ideation (assessed via the Columbia Suicide Severity Rating Scale)
-
Severe executive dysfunction (based on clinical judgment during screening evaluation) precluding use of the iPad
-
Severe depression-even in the absence of active suicidal ideation-based on the screening evaluation and clinical judgment of the PI, which warrants a higher level of care and/or immediate referral to psychiatric services.
-
pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Weill Cornell Medical Center | New York | New York | United States | 10065 |
Sponsors and Collaborators
- Weill Medical College of Cornell University
- National Institute of Mental Health (NIMH)
Investigators
- Principal Investigator: Abhishek Jaywant, PhD, Weill Medical College of Cornell University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21-11024159; 1K23MH129849-01A1